Equity
●
Pharma & Health Care
Current NAV
₹512.00
Expense Ratio
1.82%
Min SIP
₹100
Fund Size
₹8737Cr
Min Investment
₹5.00K
Lock In
NA
Scheme Information Document
Exit load: 1% on or before 1M, Nil after 1M
Alpha
-0.00%
Beta
0.92
Sharpe Ratio
0.344984
Risk
22.42%
Above numbers are based upon past 3 years
Would have become
₹1,49,748.59
(-1.40)%
| Name | Holding(%) |
| Name | Sector(%) |
| Name | Assets(%) |
Sailesh Raj Bhan
Nippon India Pharma FundTotal assets under management
₹573.67L Crores
Date of incorporation
24 Feb 1995
Ans.
Go to the Rupeezy App
Ans. The Nippon India Pharma Fund has an AUM of ₹8736.57 Cr as on 9/8/2025. The scheme has delivered CAGR returns for the past 3 years against a category average of 23.23%. The risk is Very High against the category average of 87.11.
Ans. Mutual fund taxation depends on the scheme type and investment holding period.
Taxation on equity funds: For equity funds (funds that invest at least 65% of the corpus in Indian stocks), if the holding period is more than 12 months, LTCG (Long Term Capital Gains) tax is applicable. For units sold within 12 months of purchase, STCG (Short Term Capital Gains) Tax is applicable.
LTCG tax on equity-oriented schemes is 12.5% on capital gains over ₹1.25 lakh (as per the latest update in Budget 2024).
STCG tax applicable on the sale of units of equity-oriented mutual fund schemes is 20%.
Ans. There is no lock-in period applicable on Nippon India Pharma Fund.
Ans. The expense ratio of Nippon India Pharma Fund is 1.82%.